Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

Abstract The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression w...

Full description

Bibliographic Details
Main Authors: David L. Rimm, Gang Han, Janis M. Taube, Eunhee S. Yi, Julia A. Bridge, Douglas B. Flieder, Robert Homer, Anja C. Roden, Fred R. Hirsch, Ignacio I. Wistuba, Lajos Pusztai
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Breast Cancer Research
Subjects:
Non-small cell lung cancer
PD-L1
Immunohistochemistry
Triple-negative breast cancer
Atezolizumab
Online Access:http://link.springer.com/article/10.1186/s13058-019-1156-6

Internet

http://link.springer.com/article/10.1186/s13058-019-1156-6

Similar Items